|
Daily Medical Update
Hemolytic Anemia
Wednesday, May 20, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Blood advances (2026) - Meta-Analysis
Key Findings
- Hydroxyurea and chronic blood transfusion each reduced primary stroke rates to 1.0 per 100 person-years versus 10.7 with no therapy.
- Secondary stroke recurrence was 3.5 per 100 person-years with hydroxyurea versus 19.6 with no therapy, with matched-related donor allo-HCT showing the strongest prevention signal.
📋 Practice Implication: Children with sickle cell anemia who meet stroke-risk criteria should remain on hydroxyurea or chronic transfusion unless they can transition to a curative pathway, because untreated stroke risk remains markedly higher.
|
European journal of haematology (2025) - Meta-Analysis
Key Findings
- Crovalimab achieved hemolysis control in 83% of patients, with stabilized hemoglobin in 61%.
- Transfusion avoidance occurred in 65%, while serious adverse events were limited to 14% despite 90% reporting any-grade adverse events.
📋 Practice Implication: For PNH with active intravascular hemolysis, crovalimab is a credible complement-inhibitor option when the treatment goal is LDH control and transfusion reduction with acceptable serious-toxicity rates.
|
British journal of haematology (2025) - RCT
Key Findings
- Most patients improved to hemoglobin levels of at least 10.0 g/dL during luspatercept treatment.
- Many patients also had hemoglobin increases of at least 1.0 g/dL from baseline, a threshold linked to reduced morbidity and mortality.
📋 Practice Implication: In non-transfusion-dependent beta-thalassemia, luspatercept should be considered when the practical objective is to push hemoglobin above clinically meaningful thresholds rather than waiting for transfusion dependence to worsen.
|
Blood advances (2025) - Meta-Analysis
Key Findings
- Continuing complement inhibitor therapy was associated with an approximately 76% reduction in relapse risk compared with stopping treatment.
- Stopping anticomplement therapy increased disease recurrence risk across the pooled observational evidence.
📋 Practice Implication: Any plan to stop eculizumab in atypical HUS should be treated as a high-relapse decision that requires a clear monitoring and rescue strategy rather than routine de-escalation.
|
European journal of clinical microbiology & infectious diseases (2025) - Meta-Analysis
Key Findings
- Any antibiotic exposure increased HUS risk in E. coli O157 infection (odds ratio 1.47, 95% CI 1.03-2.09).
- Beta-lactam use showed an even larger HUS risk increase (odds ratio 2.37, 95% CI 1.79-3.15).
📋 Practice Implication: When Shiga toxin-producing E. coli O157 is suspected, empiric antibiotics, especially beta-lactams, should be avoided unless another clear indication exists because treatment may precipitate HUS.
|
|
💡
Summary
Recent hemolytic-anemia evidence was dominated by disease-specific studies in sickle cell anemia, paroxysmal nocturnal hemoglobinuria, thalassemia, and hemolytic uremic syndromes rather than umbrella reviews across all causes. The strongest signals favored stroke prophylaxis and disease-modifying therapy in sickle cell anemia, effective complement blockade in PNH and atypical HUS, and luspatercept for non-transfusion-dependent beta-thalassemia, while also reinforcing antibiotic caution in Escherichia coli O157 infection because of higher HUS risk. Overall, the update supports subtype-specific management that prioritizes relapse prevention, transfusion avoidance, and organ protection.
|
|